Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program

被引：15

作者：

Bertho, Marion ^{[2
]}

Fraisse, Julien ^{[3
]}

Patsouris, Anne ^{[2
]}

Cottu, Paul ^{[4
]}

Arnedos, Monica ^{[5
]}

Perol, David ^{[6
]}

Jaffre, Anne ^{[7
]}

Goncalves, Anthony ^{[8
]}

Lebitasy, Marie-Paule ^{[9
]}

D'Hondt, Veronique ^{[10
]}

Dalenc, Florence ^{[11
]}

Ferrero, Jean-Marc ^{[12
]}

Levy, Christelle ^{[13
]}

Dabakuyo, Sandrine ^{[14
]}

Rouzier, Roman ^{[15
]}

Penault-Llorca, Frederique ^{[16
]}

Uwer, Lionel ^{[17
]}

Eymard, Jean-Christophe ^{[18
]}

Breton, Mathias ^{[19
]}

Chevrot, Michael ^{[20
]}

Thureau, Sebastien ^{[21
]}

Petit, Thierry ^{[22
]}

Simon, Gaetane ^{[20
]}

Frenel, Jean-Sebastien ^{[1
]}

机构：

[1] ICO Rene Gauducheau, Dept Med Oncol, Blvd Jacques Monod, F-44805 Pays De La Loire, France

[2] Inst Cancerol Ouest Paul Papin, Dept Med Oncol, Angers, France

[3] Reg Canc Inst Montpellier ICM, Biometr Unit, Montpellier, France

[4] Inst Curie, Dept Med Oncol, Paris, France

[5] Gustave Roussy Canc Campus, Dept Med Oncol, Villejuif, France

[6] Ctr Leon Berard, Biostat Unit, Clin Res & Innovat Dept, Lyon, France

[7] Inst Bergonie, Dept Med Informat, Bordeaux, France

[8] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France

[9] Ctr Oscar Lambret, Clin Res & Innovat Dept, Lille, France

[10] Inst Canc Montpellier, Dept Med Oncol, Montpellier, France

[11] IUCT Oncopole, Dept Med Oncol, Inst Claudius Regaud, Toulouse, France

[12] Inst Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France

[13] Ctr Francois Baclesse, Dept Med Oncol, Caen, France

[14] Ctr Georges Francois Leclerc, Natl Qual Life & Canc Clin Res Platform, Dijon, France

[15] Inst Curie, Dept Surg Oncol, St Cloud, France

[16] Ctr Jean Perrin, Dept Pathol & Mol Pathol, Clermont Ferrand, France

[17] Inst Cancerol Lorraine, Dept Med Oncol, Vandoeuvre Les Nancy, France

[18] Inst Cancerol Jean Godinot, Dept Med Oncol, Reims, France

[19] Ctr Eugene Marquis, Dept Med Informat, Rennes, France

[20] UNICANCER R&D, Paris, France

[21] Ctr Henri Becquerel, Dept Radiat Oncol, Rouen, France

[22] Ctr Paul Strauss, Dept Med Oncol, Strasbourg, France

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷

关键词：

bone-only; metastatic breast cancer; outcomes; overall survival; real-life; treatments; ZOLEDRONIC ACID; DOUBLE-BLIND; SKELETAL COMPLICATIONS; PROPENSITY SCORE; CLINICAL COURSE; SURVIVAL; FULVESTRANT; COMBINATION; WOMEN; TRASTUZUMAB;

D O I：

10.1177/1758835920987657

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. Methods: Using the French national multicenter ESME (Epidemiological Strategy and Medico Economics) Data Platform, the primary objective of our study was to compare the overall survival (OS) of patients with BO versus non-BO MBC at diagnosis, with adjustment on main prognostic factors using a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1), describe treatment patterns, and estimate factors associated with OS. Results: Out of 20,095 eligible women, 5041 (22.4%) patients had BO disease [hormone-receptor positive (HR+)/human epidermal growth-factor-receptor-2 negative (HER2-), n = 4 102/13,229 (31%); HER2+, n = 644/3909 (16.5%); HR-/HER2-, n = 295/2 957 (10%)]. BO MBC patients had a better adjusted OS compared with non-BO MBC [52.1 months (95% confidence interval (CI) 50.3-54.1) versus 34.7 months (95% CI 34.0-35.6) respectively]. The 5-year OS rate of BO MBC patients was 43.4% (95% CI 41.7-45.2). They also had a better PFS1 [13.1 months (95% CI 12.6-13.8) versus 8.5 months (95% CI 8.3-8.7), respectively]. This observation could be repeated in all subtypes. BO disease was an independent prognostic factor of OS [hazard ratio 0.68 (95% CI 0.65-0.72), p < 0.0001]. Results were concordant in all analyses. Conclusion: BO MBC patients have better outcomes compared with non-BO MBC, consistently, through all MBC subtypes.

引用

页数：15